The Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine disorders among women of reproductive age that can cause irregular menstrual periods, excess androgen levels, infertility issues and other metabolic disorders. PCOS diagnostic tests help in early detection of the condition by analyzing hormonal levels, ultrasound scans and other clinical symptoms. The global PCOS diagnostic Market is estimated to be valued at US$ 780 million in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising Awareness Regarding PCOS: PCOS is a widespread but under-diagnosed condition. However, awareness regarding PCOS and its diagnostic tests is increasing significantly among the general population as well as medical fraternity. Various initiatives undertaken by governments and health organizations to spread knowledge about PCOS symptoms and importance of early diagnosis are fueling the growth of PCOS diagnostic market. With enhanced awareness, more women are opting for routine health checkups and diagnostic tests for detecting PCOS at an early stage, thereby driving the demand for PCOS diagnosis over the forecast period.
SWOT Analysis
Strength: Diagnosis of PCOS has become more accurate with the advancement of diagnostic tools and equipment available. This helps identify health risks at an early stage.
Weakness: Lack of awareness about PCOS symptoms among women. Many cases remain undiagnosed.
Opportunity: Growing health awareness drives the demand for diagnostic tests. Rising focus on women’s health presents an opportunity to introduce low-cost diagnostic solutions.
Threats: High cost of advanced diagnostic devices restricts their adoption in low and middle-income regions. Stringent regulations delay market approvals.
Key Takeaways
The global PCOS diagnostic market is expected to witness high growth.
Regional analysis comprised North America currently dominates the market owing to the availability of advanced diagnostic infrastructure and high healthcare spending. The Asia Pacific region is expected to witness the fastest growth rate over the forecast period backed by growing medical tourism, increasing healthcare spending and improving medical facilities.
Key players operating in the PCOS diagnostic Market are: Merck KGaA, Abbott, bioMérieux SA , Church & Dwight Co., Inc., Cardinal Health, Quest Diagnostics, DDiagnostic Automation/Cortez Diagnostics Inc, FUJIFILM Irvine Scientific, bio TECHNE, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Danaher, Agilent Technologies, Inc., CooperSurgical, Inc., Medtronic , Cook, Ethicon, and B. Braun Melsungen AG.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it